← All China Pharma Holdings, INC filings

China Pharma Holdings, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

AMEX
CPHI
China Pharma Holdings, INC
10-Q: China Pharma Holdings Faces Going Concern Amid Revenue Decline
China Pharma Holdings reports continued net losses and declining revenue, raising substantial doubt about its ability to continue as a going concern.
AMEX
CPHI
China Pharma Holdings, INC
10-Q: China Pharma Holdings Faces Going Concern Doubts Amid Losses
China Pharma Holdings, Inc. reported a reduced net loss for the first half of 2025, but continues to face substantial doubt about its ability to continue as a going concern.
AMEX
CPHI
China Pharma Holdings, INC
10-Q: China Pharma Holdings Reports Q1 2025 Results: Revenue Declines Amid Generic Drug Competition
China Pharma Holdings saw a decrease in revenue for the first quarter of 2025, primarily due to increased competition from generic drugs in China.
AMEX
CPHI
China Pharma Holdings, INC
10-Q: China Pharma Holdings Reports Q3 2024 Results: Revenue Declines Amidst Market Challenges
China Pharma Holdings experienced a decrease in revenue during the third quarter of 2024, primarily due to increased competition and the impact of centralized procurement policies in China.
AMEX
CPHI
China Pharma Holdings, INC
10-Q: China Pharma Holdings Reports Q2 2024 Results: Revenue Declines Amidst Market Challenges
China Pharma Holdings reported a decrease in revenue and a net loss for the second quarter of 2024, primarily due to increased competition and the impact of centralized procurement policies in China.
AMEX
CPHI
China Pharma Holdings, INC
10-Q: China Pharma Holdings Reports Q1 2024 Results with Revenue Decline and Increased Net Loss
China Pharma Holdings experienced a 30.1% decrease in revenue and an increased net loss in the first quarter of 2024 compared to the same period in 2023.